The evidence that *Mycoplasma genitalium* is a sexually transmitted pathogen is virtually incontrovertible based on both the concordance rates among partners and on DNA typing showing the same sequence type among partners in contrast to unrelated *M genitalium* positive patients. The implications that this has for the screening, testing, and treatment of patients is less certain however. Which tests are the most sensitive and specific, what samples are most appropriate, who should be tested, what treatment is best and how should partners be managed?

The bacterium *Mycoplasma genitalium* is difficult to study. The organism is fastidious and culture is difficult and, even when successful, it takes several weeks or even months for each isolate to grow. Serology in its more sophisticated forms may have a role in epidemiological studies but is not of value in diagnosis. Hence, nucleic acid amplification tests (NAATs) are the only available diagnostic tools, but no commercially available test has been released for diagnostic purposes.

**THE EVIDENCE FOR *M GENITALIUM* AS A PATHOGEN USING ANIMAL AND TISSUE MODELS**

Studies in non-human primates have clearly demonstrated the pathogenicity of *M genitalium* in both male and female animals. *M genitalium* can be isolated from an infected animal and can be transferred to an uninfected animal and cause disease fulfilling one of Koch's postulates.

In vitro studies demonstrate the potential for *M genitalium* to attach to genital tract epithelial cells using a surface adhesin protein and then to enter the cells leading to the upregulation of cytokine genes with an associated inflammatory response. *M genitalium* can also attach to spermatozoa giving a potential mechanism for spread to the female upper genital tract.

**EVIDENCE FOR *M GENITALIUM* AS A PATHOGEN IN MEN**

Large numbers of papers on the role of *M genitalium* in male non-gonococcal urethritis (NGU) have been published since 1993 following the initial polymerase chain reaction based studies. Although different criteria have been used to define patient and control groups, all the studies have uniformly shown a higher prevalence of *M genitalium* in the NGU groups (reviewed by Jensen). Moreover, *M genitalium* appears to be detected with the highest prevalence in men with *Chlamydia trachomatis* negative NGU (NCNGU). Several studies have found that men with *M genitalium* positive NGU have symptoms as least as often as have those with chlamydial NGU. When urethritis has been graded according to the number of polymorphonuclear leucocytes (PMNLs) in the urethral smear, men with *M genitalium* have had higher PMNL counts than men with *M genitalium* negative NCNGU, indicating a significant inflammatory potential. Systematic studies linking *M genitalium* to complications such as epididymitis and prostatitis are lacking although *M genitalium* DNA has been found both in the urethra of men with epididymitis, and in prostatic tissue of men with prostatitis.

**EVIDENCE FOR *M GENITALIUM* AS A PATHOGEN IN WOMEN**

In women, *M genitalium* can be detected in the genital tract and is found most commonly in those with genital tract symptoms or signs, or those who have an infected male partner. The presence of *M genitalium* is associated with cervicitis and urethritis in women and the inoculation of *M genitalium* in non-human primates leads to both lower genital tract disease and salpingitis. *M genitalium* can be detected in the endometrium of women with pelvic inflammatory disease and, on a single occasion, has been found in the fallopian tube. In addition, serological studies suggest a strong association between past infection with *M genitalium* and tubal factor infertility. It therefore seems very likely that *M genitalium* is a sexually transmitted pathogen in women and responsible for at least some cases of urethritis, cervicitis, and pelvic inflammatory disease.

**HOW TO DIAGNOSE *M GENITALIUM*: CURRENT AVAILABILITY OF TESTING AND FUTURE PROSPECTS**

At present, NAATs are the only tools available for detection of *M genitalium*. Because of a very low load of mycoplasmas in some patients, tests with a very low limit of detection are needed in order to achieve sufficient assay sensitivity. No approved commercial assays have been made available although promising results with kits for research use have been presented. In the years to come, it is likely that more sensitive and specific forms of NAAT may have a role in epidemiological studies but is not of value in diagnostic use and may find a role in research use.

**Abbreviations:** NAATs, nucleic acid amplification tests; NGU, non-gonococcal urethritis; PMNLs, polymorphonuclear leucocytes; STI, sexually transmitted infections.

---

**Correspondence to:** Professor J Ross, Whittall Street Clinic, Whittall Street, Birmingham B4 6DH, UK; jonathan.ross@hobtpct.nhs.uk

**Accepted for publication** 23 March 2006

**See end of article for authors’ affiliations**
to come, approved assays will most likely become available, but until then it is imperative that laboratories actively engage in external quality assurance programmes using real clinical specimens before they offer NAATs on a routine basis. The optimal specimen type may vary depending on the sample preparation method used in the laboratory. In one large study male first void urine was found to detect more infections with *M. genitalium*, as well as with *Chlamydia trachomatis*, than urethral swabs although this might reflect the amount of specimen used in the sample preparation method. In women the use of more than one specimen may also improve diagnostic sensitivity—for example, supplementing a urine specimen with a cervical swab.

**ANTIBIOTIC THERAPY FOR *M. GENITALIUM* INFECTIONS**

A number of different antibiotics have been used to treat *M. genitalium* infections with varying degrees of success. Tetracyclines initially looked promising but more recent studies suggest that failure to fully eradicate the infection occurs in a high proportion of cases treated with these agents. Macrolides, in particular azithromycin, offer the best chance of cure with a 84% clearance in a recent randomised controlled trial performed in men with *M. genitalium* urethritis. The newer quinolones, such as moxifloxacin, also have good activity against *M. genitalium* in vitro (although ciprofloxacin and ofloxacin are less effective). 

Because *M. genitalium* grows very slowly a prolonged course of therapy may be required to eradicate it. In a preliminary open study from Scandinavia a trend towards improved outcome with longer duration of therapy was observed—azithromycin 1 g immediately eradicated 85% (11/13) of the *M. genitalium* infections whereas a dose of 500 mg on day 1 followed by 250 mg daily for 4 days eradicated 95% (19/20) of infections.

**Recommendations**

With the current state of knowledge of *M. genitalium* what interim recommendations can be given about screening, testing, and management?

**Screening**

It is premature to start population screening for *M. genitalium*. To do so we need accurate information on the prevalence of infection and prospective data on the natural history of disease in infected individuals. Only with this information can the efficacy and cost effectiveness of screening be calculated for different populations. The proposed testing of urine samples for *M. genitalium* from the NATSAL study will provide essential prevalence information to help inform the role of screening in the future. The evidence linking *M. genitalium* to pelvic inflammatory disease is strong but largely circumstantial and we still lack natural history studies which demonstrate a temporal relation between infection and disease. At least one such study is ongoing in the United States and another is planned for the United Kingdom, which will help to quantitate the risk of pelvic infection associated with *M. genitalium* infection and define the role of screening.

**Testing**

Although a variety of “in-house” PCRs have been developed there is a clear and urgent need for an accurate, standardised, and quality assured test kit for *M. genitalium*. Assuming a test is available who should be tested for *M. genitalium*?

Testing men with symptomatic NGU is reasonable, in particular in those settings where empirical treatment with doxycycline is used. Two thirds of the *M. genitalium* infected patients with urethritis will have persistent infection and often experience recurrent symptoms after doxycycline therapy. The same argument could also be used to justify testing patients presenting with complications such as epididymitis, prostatitis, and sexually acquired reactive arthritis.

Testing for *M. genitalium* in women presenting with genital tract symptoms, such as genital discharge, intermenstrual bleeding, or pelvic pain is justified because of the association between *M. genitalium* and cervicitis, endometritis, and clinical pelvic inflammatory disease. Further information on the natural history and prevalence of infection is needed before testing of asymptomatic women can be recommended.

**Treatment**

Specific treatment for *M. genitalium* is appropriate in symptomatic patients in whom the organism has been detected and current evidence suggests that first line therapy with a 3 day course of azithromycin would be most appropriate. Single doses of azithromycin may be less effective in men with urethritis and occasionally macrolide resistance has been encountered. Patients with treatment failure after azithromycin have been successfully treated with moxifloxacin 400 mg daily for 10 days but because of the risk of development of resistance this treatment should be considered second line.

The lack of prospective natural history data makes a firm recommendation to trace and treat all sexual contacts premature at present, but such an approach is reasonable for individual patients after appropriate discussion.

**Summary**

Based on the current evidence a recommendation to test patients with genital symptoms for *M. genitalium* is justified and treatment of those found to be infected should be with azithromycin. The scope for testing will, however, be limited until validated and, preferably, commercially available tests become accessible.

**Key messages**

- *Mycoplasma genitalium* is now established as a sexually transmitted infection
- The role of screening for infection is currently unknown
- Testing and treatment of symptomatic individuals infected with *M. genitalium* is recommended, but limited by the lack of suitable tests
- Current evidence supports the use of azithromycin as first line therapy for *M. genitalium*

**Authors’ affiliations**

J D Ross, Whitall Street Clinic, Birmingham B4 6DH, UK
J S Jensen, Statens Serum Institut, Amfi留存区的，DK-2300 Copenhagen S, Denmark

Declaration of interests: JR has received consultancy fees from Bayer and Pfizer and is an associate editor of Sexually Transmitted Infections. JR and JJ jointly wrote and revised the manuscript.

**REFERENCES**


